|
See related Cubicin infusion information |
|
|
|
Manufacturer |
AstraZeneca |
|
Distributor |
DKSH |
|
Contents |
Daptomycin |
|
Indications |
Infections caused by gm +ve bacteria only. Complicated skin & skin structure infections, Staph aureus bacteremia including right-sided infective endocarditis, methicillin-susceptible & -resistant isolates in adults.
Click to view Cubicin detailed prescribing infomation |
|
Dosage |
IV infusion over 30 min. Adult Complicated skin & skin structure infections 4 mg/kg once every 24 hr for 7-14 days. Staphylococcus aureus bacteremia including right-sided endocarditis 6 mg/kg once every 24 hr for 2-6 wk. Patient w/ CrCl <30mL/min Increase dose interval to a single dose once every 48 hr.
Click to view Cubicin detailed prescribing infomation |
|
Overdosage |
View Cubicin overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity.
Click to view Cubicin detailed prescribing infomation |
|
Special Precautions |
Neuropathy, renal insufficiency. Monitor plasma creatine phosphokinase (CPK) & renal function. Discontinue in case of unexplained muscle symptoms if CPK is >1,000 u/L or if asymptomatic but CPK is >2,000 u/L. Lactation.
Click to view Cubicin detailed prescribing infomation |
|
Adverse Drug Reactions |
Anemia, eosinophilia, thrombocytosis, supraventricular arrhythmia, vertigo, GI disorders, fatigue, infusion site reactions, pyrexia, rigors, jaundice, fungal infections, UTI, decreased appetite, hyperglycemia, arthralgia, muscle pain/weakness, rhabdomyolysis, dizziness, headache, paresthesia, taste disorder, anxiety, insomnia, vaginitis, rash, pruritis, uriticaria, flushes, HTN, hypotension.
View ADR Monitoring Form |
|
Drug Interactions |
HMG-CoA reductase inhibitors, tobramycin, dextrose-containing diluents.
View more drug interactions with Cubicin |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Cubicin detailed prescribing infomation |
|
Storage |
View Cubicin storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Cubicin description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Cubicin mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Cubicin infusion |
|
Cubicin 500 mg x 1's |
 |
|
|
|
Manufacturer: |
AstraZeneca |
|
Distributor: |
DKSH |
|
 |
|
|
|
